| VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium (NCT00407485) | National Cancer Institute (NCI) | 2006-11-01 |
| Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (NCT00365157) | National Cancer Institute (NCI) | 2006-10-23 |
| AZD2171 to Treat Prostate Cancer (NCT00436956) | National Cancer Institute (NCI) | 2006-10-16 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00407966) | National Cancer Institute (NCI) | 2006-10-01 |
| Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus (NCT00378911) | National Cancer Institute (NCI) | 2006-10-01 |
| Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) (NCT00365209) | National Cancer Institute (NCI) | 2006-10-01 |
| Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors (NCT00454376) | National Cancer Institute (NCI) | 2006-10-01 |
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes (NCT00393029) | National Cancer Institute (NCI) | 2006-10-01 |
| Sunitinib in Treating Young Patients With Refractory Solid Tumors (NCT00387920) | National Cancer Institute (NCI) | 2006-10-01 |
| Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases (NCT00390468) | National Cancer Institute (NCI) | 2006-10-01 |
| Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab (NCT00387374) | National Cancer Institute (NCI) | 2006-10-01 |
| Lycopene in Healthy Male Participants (NCT00450957) | National Cancer Institute (NCI) | 2006-10-01 |
| AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer (NCT00410904) | National Cancer Institute (NCI) | 2006-10-01 |
| VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer (NCT00407654) | National Cancer Institute (NCI) | 2006-10-01 |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455) | National Cancer Institute (NCI) | 2006-09-15 |
| Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (NCT00267865) | National Cancer Institute (NCI) | 2006-09-14 |
| A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00409565) | National Cancer Institute (NCI) | 2006-09-01 |
| Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism (NCT01361165) | National Cancer Institute (NCI) | 2006-09-01 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis (NCT00387426) | National Cancer Institute (NCI) | 2006-09-01 |
| FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00383565) | National Cancer Institute (NCI) | 2006-09-01 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma (NCT00390234) | National Cancer Institute (NCI) | 2006-09-01 |
| Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors (NCT00301756) | National Cancer Institute (NCI) | 2006-09-01 |
| Bevacizumab and Irinotecan to Treat Brain Tumors (NCT00393094) | National Cancer Institute (NCI) | 2006-09-01 |
| Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00377104) | National Cancer Institute (NCI) | 2006-09-01 |
| Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery (NCT00381641) | National Cancer Institute (NCI) | 2006-08-29 |
| Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer (NCT00369122) | National Cancer Institute (NCI) | 2006-08-11 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia (NCT00381550) | National Cancer Institute (NCI) | 2006-08-01 |
| VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide (NCT00369590) | National Cancer Institute (NCI) | 2006-08-01 |
| Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer (NCT00387465) | National Cancer Institute (NCI) | 2006-08-01 |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase (NCT00383474) | National Cancer Institute (NCI) | 2006-08-01 |
| Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer (NCT00305734) | National Cancer Institute (NCI) | 2006-08-01 |
| Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT00387335) | National Cancer Institute (NCI) | 2006-08-01 |
| Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma (NCT00381797) | National Cancer Institute (NCI) | 2006-08-01 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00313586) | National Cancer Institute (NCI) | 2006-08-01 |
| Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer (NCT00365391) | National Cancer Institute (NCI) | 2006-08-01 |
| Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients (NCT00383760) | National Cancer Institute (NCI) | 2006-08-01 |
| Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer (NCT00258349) | National Cancer Institute (NCI) | 2006-08-01 |
| S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer (NCT00368992) | National Cancer Institute (NCI) | 2006-08-01 |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma (NCT00365274) | National Cancer Institute (NCI) | 2006-08-01 |
| Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia (NCT00368927) | National Cancer Institute (NCI) | 2006-08-01 |
| Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma (NCT00387751) | National Cancer Institute (NCI) | 2006-08-01 |
| Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer (NCT00321685) | National Cancer Institute (NCI) | 2006-07-25 |
| Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT00376688) | National Cancer Institute (NCI) | 2006-07-11 |
| A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China (NCT00559065) | National Cancer Institute (NCI) | 2006-07-11 |
| Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) (NCT00923169) | National Cancer Institute (NCI) | 2006-07-09 |
| Collection of Tissue Samples for Cancer Research (NCT00900198) | National Cancer Institute (NCI) | 2006-07-06 |
| Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease (NCT00904579) | National Cancer Institute (NCI) | 2006-07-01 |
| Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00669019) | National Cancer Institute (NCI) | 2006-07-01 |
| Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer (NCT00362882) | National Cancer Institute (NCI) | 2006-07-01 |
| Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer (NCT00368875) | National Cancer Institute (NCI) | 2006-07-01 |
| AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery (NCT00348699) | National Cancer Institute (NCI) | 2006-07-01 |
| Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium (NCT00559767) | National Cancer Institute (NCI) | 2006-06-30 |
| Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT00334815) | National Cancer Institute (NCI) | 2006-06-15 |
| Cancer Markers Associated With Occupational Exposure to Trichloroethylene (NCT00481611) | National Cancer Institute (NCI) | 2006-06-15 |
| Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (NCT00334789) | National Cancer Institute (NCI) | 2006-06-12 |
| Association of Formaldehyde Exposure to Myeloid Leukemia in Workers in Guangdong, China (NCT01338285) | National Cancer Institute (NCI) | 2006-06-10 |
| Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 (NCT00314119) | National Cancer Institute (NCI) | 2006-06-08 |
| Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia (NCT00360776) | National Cancer Institute (NCI) | 2006-06-02 |
| Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer (NCT00369551) | National Cancer Institute (NCI) | 2006-06-01 |
| Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer (NCT00454571) | National Cancer Institute (NCI) | 2006-06-01 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (NCT00351975) | National Cancer Institute (NCI) | 2006-06-01 |
| AFP464 in Treating Patients With Advanced Solid Tumors (NCT00369200) | National Cancer Institute (NCI) | 2006-06-01 |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia (NCT00352365) | National Cancer Institute (NCI) | 2006-06-01 |
| Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) (NCT00330421) | National Cancer Institute (NCI) | 2006-06-01 |
| Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia (NCT00363779) | National Cancer Institute (NCI) | 2006-06-01 |
| Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma (NCT00363272) | National Cancer Institute (NCI) | 2006-06-01 |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases (NCT00357708) | National Cancer Institute (NCI) | 2006-06-01 |
| Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia (NCT00369174) | National Cancer Institute (NCI) | 2006-06-01 |
| Bevacizumab and Sunitinib in Treating Patients With Solid Tumors (NCT00357318) | National Cancer Institute (NCI) | 2006-06-01 |
| Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium (NCT00363883) | National Cancer Institute (NCI) | 2006-06-01 |
| Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT00262925) | National Cancer Institute (NCI) | 2006-06-01 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00293345) | National Cancer Institute (NCI) | 2006-06-01 |
| PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery (NCT00365053) | National Cancer Institute (NCI) | 2006-06-01 |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia (NCT01445080) | National Cancer Institute (NCI) | 2006-05-30 |
| BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer (NCT00326495) | National Cancer Institute (NCI) | 2006-05-10 |
| LMB-2 to Treat Hairy Cell Leukemia (NCT00321555) | National Cancer Institute (NCI) | 2006-05-02 |
| S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer (NCT00337129) | National Cancer Institute (NCI) | 2006-05-01 |
| Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors (NCT00356889) | National Cancer Institute (NCI) | 2006-05-01 |
| AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (NCT00321724) | National Cancer Institute (NCI) | 2006-05-01 |
| Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery (NCT00321594) | National Cancer Institute (NCI) | 2006-05-01 |
| CDDO to Treat Solid Tumors and Lymphomas (NCT00322140) | National Cancer Institute (NCI) | 2006-05-01 |
| AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia (NCT00321581) | National Cancer Institute (NCI) | 2006-05-01 |
| Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00354250) | National Cancer Institute (NCI) | 2006-05-01 |
| PXD101 in Treating Patients With Acute Myeloid Leukemia (NCT00357032) | National Cancer Institute (NCI) | 2006-05-01 |
| Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00316849) | National Cancer Institute (NCI) | 2006-05-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma (NCT00354185) | National Cancer Institute (NCI) | 2006-05-01 |
| Belinostat in Treating Patients With Myelodysplastic Syndromes (NCT00357162) | National Cancer Institute (NCI) | 2006-05-01 |
| AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine (NCT00326872) | National Cancer Institute (NCI) | 2006-05-01 |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer (NCT00328861) | National Cancer Institute (NCI) | 2006-05-01 |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (NCT00326898) | National Cancer Institute (NCI) | 2006-04-24 |
| Benign Reproductive Tissue Analysis for Endometrial Cancer Markers (NCT00481754) | National Cancer Institute (NCI) | 2006-04-24 |
| Isolation and Characterization of Mammary Stem Cells (NCT00340392) | National Cancer Institute (NCI) | 2006-04-07 |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (NCT00310180) | National Cancer Institute (NCI) | 2006-04-07 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT00349206) | National Cancer Institute (NCI) | 2006-04-01 |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (NCT00335764) | National Cancer Institute (NCI) | 2006-04-01 |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma (NCT00314106) | National Cancer Institute (NCI) | 2006-04-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT01851408) | National Cancer Institute (NCI) | 2006-04-01 |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer (NCT00278343) | National Cancer Institute (NCI) | 2006-04-01 |
| Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (NCT00334893) | National Cancer Institute (NCI) | 2006-04-01 |